DXR-IN-3, identified by its CAS number 1465907-72-5, is a chemical compound that has garnered attention in the field of medicinal chemistry, particularly for its potential applications in cancer treatment. As a small molecule inhibitor, it is designed to target specific pathways involved in tumor growth and proliferation. The compound exhibits a unique structure that allows it to interact with biological targets, potentially leading to the modulation of cellular processes. Its efficacy and safety profile are typically evaluated through preclinical and clinical studies, focusing on its pharmacokinetics, bioavailability, and mechanism of action. Additionally, DXR-IN-3 may demonstrate solubility characteristics that influence its formulation and delivery in therapeutic contexts. As research continues, understanding its interactions at the molecular level will be crucial for optimizing its use in clinical settings. Overall, DXR-IN-3 represents a promising avenue in the ongoing search for effective cancer therapies.

DXR-IN-3

1465907-72-5: DXR-IN-3, identified by its CAS number 1465907-72-5, is a chemical compound that has garnered attention in the field of medicinal chemistry, particularly for its potential applications in cancer treatment. As a small molecule inhibitor, it is designed to target specific pathways involved in tumor growth and proliferation. The compound exhibits a unique structure that allows it to interact with biological targets, potentially leading to the modulation of cellular processes. Its efficacy and safety profile are typically evaluated through preclinical and clinical studies, focusing on its pharmacokinetics, bioavailability, and mechanism of action. Additionally, DXR-IN-3 may demonstrate solubility characteristics that influence its formulation and delivery in therapeutic contexts. As research continues, understanding its interactions at the molecular level will be crucial for optimizing its use in clinical settings. Overall, DXR-IN-3 represents a promising avenue in the ongoing search for effective cancer therapies.

<p>DXR-IN-3 is an anti-Toxoplasma DXR inhibitor. It exhibits in vitro activity against the TgDXR enzyme, with an IC50 value of 0.62 μM and a Ki value of 0.19 μM. Furthermore, DXR-IN-3 can inhibit the proliferation of Toxoplasma, displaying an IC50 value of 5.46 μM.</p>

CAS 1465907-72-5

DXR-IN-3

DXR-IN-3

Ref: TM-T200712